Lysa
04 décembre 2020
Le LYSA au 62ème Congrès de l’ASH
Le 62ème Congrès de l'ASH (American Society of Hematology) se déroulera du 05 au 08 décembre 2020 en format virtuel
11 abstracts LYSA ont été sélectionnés !
Découvrez les abstracts :
3 communications orales LYSA :
- Ro-Chop : final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma | Emmanuel Bachy
- AHL 2011 : PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study | Olivier Casasnovas
- MRD LyMA : Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group | Mary Callanan
8 posters LYSA :
- R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of LYSA Centers | Vincent Camus
- Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial” | Olivier Tournilhac
- Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial | Louise Bouard
- Lenalidomide As Maintenance Therapy after R-CHOP Has No Protecting Effect for Central Nervous System Relapse in Frontline Treatment of Diffuse Large B-Cells Lymphoma. an Ancillary Studies of the Remarc Study | Sophie Bernard
- The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World | Catherine Thieblemont
- Amahrelis: Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma: A Real Life Study from Sfgmtc and LYSA Groups | Amira Marouf
- Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial | Roch Houot
- Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network, a LYSA Project | Fabrice Jardin